From Sorafenib to Precision Medicine: The Future of Systemic Therapy in Hepatocellular Carcinoma ...

From Sorafenib to Precision Medicine: The Future of Systemic Therapy in Hepatocellular Carcinoma  ASCO Daily News

Retrospective analysis of sorafenib combined with interferon α-1b, interleukin-2, and thalidomide...

Retrospective analysis of sorafenib combined with interferon α-1b, interleukin-2, and thalidomide as maintenance therapy in FLT3-ITD-positive acute myeloid leukemia  Frontiers

D-lactate and glycerol as potential biomarkers of sorafenib activity in hepatocellular carcinoma ...

D-lactate and glycerol as potential biomarkers of sorafenib activity in hepatocellular carcinoma  Nature

Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable...

Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial  The Lancet

Fluorinated Proteolysis Targeting Chimeras-Sorafenib Nanoassembly for Epigenetic Remodeling to Co...

Fluorinated Proteolysis Targeting Chimeras-Sorafenib Nanoassembly for Epigenetic Remodeling to Combat Multi-Pathway Drug Resistance in Hepatocellular Carcinoma  ACS Publications

Sorafenib (Nexavar): What patients need to know? - Oncodaily

Sorafenib (Nexavar): What patients need to know?  Oncodaily

Paris court invalidates crucial claim of Bayer’s sorafenib patent - JUVE Patent

Paris court invalidates crucial claim of Bayer’s sorafenib patent  JUVE Patent

MOF enhances the sensitivity and selectivity of sorafenib as an anticancer drug against hepatocel...

MOF enhances the sensitivity and selectivity of sorafenib as an anticancer drug against hepatocellular carcinoma and colorectal cancer in vitro | Scientific Reports  Nature

Efficacy and safety of sorafenib combined with transarterial chemoembolization in the treatment o...

Efficacy and safety of sorafenib combined with transarterial chemoembolization in the treatment of hepatocellular carcinoma: a meta-analysis of randomized controlled trials  Frontiers

LEVIATHAN Study Results: Lenvatinib vs Sorafenib as 2L Treatment for Hepatocellular Carcinoma - O...

LEVIATHAN Study Results: Lenvatinib vs Sorafenib as 2L Treatment for Hepatocellular Carcinoma  Oncodaily

LINC00162 silencing enhances sorafenib sensitivity and inhibits thyroid cancer cells progression ...

LINC00162 silencing enhances sorafenib sensitivity and inhibits thyroid cancer cells progression through modulation of MAPK signaling and apoptosis  Nature

Mechanisms of sorafenib-induced cardiotoxicity: ER stress induces upregulation of ATF3, leading t...

Mechanisms of sorafenib-induced cardiotoxicity: ER stress induces upregulation of ATF3, leading to downregulation of NDUFS1 expression and mitochondrial dysfunction  Frontiers

ZEB1 stratifies the response to Sorafenib and Mdivi-1 combination therapy in hepatocellular carci...

ZEB1 stratifies the response to Sorafenib and Mdivi-1 combination therapy in hepatocellular carcinoma  Nature

Matrix stiffness regulates glucose-6-phosphate dehydrogenase expression to mediate sorafenib resi...

Matrix stiffness regulates glucose-6-phosphate dehydrogenase expression to mediate sorafenib resistance in hepatocellular carcinoma through the ITGB1-PI3K/AKT pathway  Nature

Targeting SIX2 as a novel sensitization strategy of sorafenib treatment on advanced hepatocellula...

Targeting SIX2 as a novel sensitization strategy of sorafenib treatment on advanced hepatocellular carcinoma through modulating METTL9-SLC7A11 axis  Nature

SLC25A39 regulates Hedgehog signaling to promote tumor progression and sorafenib resistance in he...

SLC25A39 regulates Hedgehog signaling to promote tumor progression and sorafenib resistance in hepatocellular carcinoma  Nature

Immune system development-related signature predicts prognosis and sorafenib-treatment resistance...

Immune system development-related signature predicts prognosis and sorafenib-treatment resistance of hepatocellular carcinoma by intergrating machine learning and single-cell analyses | Scientific Reports  Nature

Targeting MCM10 disrupts cancer stemness and counteracts sorafenib resistance in hepatocellular c...

Targeting MCM10 disrupts cancer stemness and counteracts sorafenib resistance in hepatocellular carcinoma  Nature

Pifithrin-μ sensitizes mTOR-activated liver cancer to sorafenib treatment - Nature

Pifithrin-μ sensitizes mTOR-activated liver cancer to sorafenib treatment  Nature

Vitamin B17 alleviates Sorafenib-induced cardiotoxicity in Ehrlich Ascites Carcinoma mice via mod...

Vitamin B17 alleviates Sorafenib-induced cardiotoxicity in Ehrlich Ascites Carcinoma mice via modulation of inflammatory and fibrotic pathways | Scientific Reports  Nature

CSF3R-AS promotes hepatocellular carcinoma progression and sorafenib resistance through the CSF3R...

CSF3R-AS promotes hepatocellular carcinoma progression and sorafenib resistance through the CSF3R/JAK2/STAT3 positive feedback loop  Nature

NCOA5 induces sorafenib resistance in hepatocellular carcinoma by inhibiting ferroptosis - Nature

NCOA5 induces sorafenib resistance in hepatocellular carcinoma by inhibiting ferroptosis  Nature

Anlotinib/Penpulimab Enhances Survival vs Sorafenib in Unresectable HCC - CancerNetwork

Anlotinib/Penpulimab Enhances Survival vs Sorafenib in Unresectable HCC  CancerNetwork

New Paper Alert: A pilot study on the neurocognitive effect of sorafenib on patients with desmoid...

New Paper Alert: A pilot study on the neurocognitive effect of sorafenib on patients with desmoid tumors  Oncodaily

Tribbles Pseudokinase 3 Converts Sorafenib Therapy to Neutrophil-Mediated Lung Metastasis in Hepa...

Tribbles Pseudokinase 3 Converts Sorafenib Therapy to Neutrophil-Mediated Lung Metastasis in Hepatocellular Carcinoma  Wiley

Fluorinated Proteolysis Targeting Chimeras-Sorafenib Nanoassembly for Epigenetic Remodeling to Co...

Fluorinated Proteolysis Targeting Chimeras-Sorafenib Nanoassembly for Epigenetic Remodeling to Combat Multi-Pathway Drug Resistance in Hepatocellular Carcinoma  ACS Publications

PIP5K1A Suppresses Ferroptosis and Induces Sorafenib Resistance by Stabilizing NRF2 in Hepatocell...

PIP5K1A Suppresses Ferroptosis and Induces Sorafenib Resistance by Stabilizing NRF2 in Hepatocellular Carcinoma  Wiley

Design and synthesis of Sorafenib analogues and evaluation of their ferroptosis-inducing effects ...

Design and synthesis of Sorafenib analogues and evaluation of their ferroptosis-inducing effects in tumor cells  ScienceDirect.com

Tremelimumab–Durvalumab Combo Extends Survival and Improves Cost-Effectiveness Over Sorafenib in ...

Tremelimumab–Durvalumab Combo Extends Survival and Improves Cost-Effectiveness Over Sorafenib in Unresectable HCC  Pharmacy Times

Anlotinib plus penpulimab versus sorafenib in the first-line treatment of unresectable hepatocell...

Anlotinib plus penpulimab versus sorafenib in the first-line treatment of unresectable hepatocellular carcinoma (APOLLO): a randomised, controlled, phase 3 trial  The Lancet

Denoised recurrence label-based deep learning for prediction of postoperative recurrence risk and...

Denoised recurrence label-based deep learning for prediction of postoperative recurrence risk and sorafenib response in HCC  bmcmedicine.biomedcentral.com

The effect of sorafenib on cognition in patients with desmoid tumor - Oncodaily

The effect of sorafenib on cognition in patients with desmoid tumor  Oncodaily

Transcription factor YBX1 orchestrates drug resistance and tumor progression in HCC - ScienceDire...

Transcription factor YBX1 orchestrates drug resistance and tumor progression in HCC  ScienceDirect.com

Yiviva Presents Phase 2b Results for YIV-906 in Combination - GlobeNewswire

Yiviva Presents Phase 2b Results for YIV-906 in Combination  GlobeNewswire

APOLLO Trial: OS Benefit with Anlotini Penpulimab in HCC - Oncodaily

APOLLO Trial: OS Benefit with Anlotini Penpulimab in HCC  Oncodaily

Sameer Rastogi Shared Early Results from SORASTOP Trial on Discontinuing Sorafenib in Desmoid Tum...

Sameer Rastogi Shared Early Results from SORASTOP Trial on Discontinuing Sorafenib in Desmoid Tumors  Oncodaily

Anlotinib Plus Penpulimab in First-Line Treatment of Unresectable Hepatocellular Carcinoma - The ...

Anlotinib Plus Penpulimab in First-Line Treatment of Unresectable Hepatocellular Carcinoma  The ASCO Post

NOX1 inhibition sensitizes HCC cells to sorafenib and radiotherapy by modulating ROS-mediated pro...

NOX1 inhibition sensitizes HCC cells to sorafenib and radiotherapy by modulating ROS-mediated programmed cell death  Nature

Phase I Study Evaluating Dose De-escalation of Sorafenib with Metformin and Atorvastatin in Hepat...

Phase I Study Evaluating Dose De-escalation of Sorafenib with Metformin and Atorvastatin in Hepatocellular Carcinoma (SMASH).  Physician's Weekly

Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for patients with unresectab...

Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for patients with unresectable hepatocellular carcinoma: a cost–utility analysis in China and the United States  Frontiers

How the chemotherapy drug sorafenib triggers muscle wasting through cell remodeling - Medical Xpress

How the chemotherapy drug sorafenib triggers muscle wasting through cell remodeling  Medical Xpress

Clinical Profile and Outcome of Patients With Advanced Hepatocellular Carcinoma (HCC) Taking Sora...

Clinical Profile and Outcome of Patients With Advanced Hepatocellular Carcinoma (HCC) Taking Sorafenib or Lenvatinib: Real-World Experience From a Low-Middle Resource Country  Cureus

Adding SBRT to sorafenib improves survival in hepatocellular carcinoma patients - News-Medical

Adding SBRT to sorafenib improves survival in hepatocellular carcinoma patients  News-Medical

Arndt Vogel Highlights HEPATORCH Trial Results Comparing Toripalimab Plus Bevacizumab with Sorafe...

Arndt Vogel Highlights HEPATORCH Trial Results Comparing Toripalimab Plus Bevacizumab with Sorafenib in Advanced HCC  Oncodaily

Combination Therapy Improves Survival in Liver Cancer - European Medical Journal

Combination Therapy Improves Survival in Liver Cancer  European Medical Journal

First-Line Immunotherapy Combo Boosts Survival in Unresectable Liver Cancer - MedPage Today

First-Line Immunotherapy Combo Boosts Survival in Unresectable Liver Cancer  MedPage Today

New Paper Alert: Hepatocellular Carcinoma - Stereotactic Body Radiotherapy vs Sorafenib Alone in ...

New Paper Alert: Hepatocellular Carcinoma - Stereotactic Body Radiotherapy vs Sorafenib Alone in the NRG Oncology/RTOG 1112 Phase 3 Randomized Clinical Trial - JAMA Oncology  Oncodaily

Simultaneous treatment with sorafenib and glucose restriction inhibits hepatocellular carcinoma i...

Simultaneous treatment with sorafenib and glucose restriction inhibits hepatocellular carcinoma in vitro and in vivo by impairing SIAH1-mediated mitophagy  Nature

Decoding Drug Interactions: Character and Degree of Pharmacokinetic In | DDDT - Dove Medical Press

Decoding Drug Interactions: Character and Degree of Pharmacokinetic In | DDDT  Dove Medical Press

Autophagy modulation attenuates sorafenib resistance in HCC induced in rats - Nature

Autophagy modulation attenuates sorafenib resistance in HCC induced in rats  Nature

CircRNA-SORE mediates sorafenib resistance in hepatocellular carcinoma by stabilizing YBX1 - Nature

CircRNA-SORE mediates sorafenib resistance in hepatocellular carcinoma by stabilizing YBX1  Nature

Ramucirumab combination with sorafenib enhances the inhibitory effect of sorafenib on HepG2 cance...

Ramucirumab combination with sorafenib enhances the inhibitory effect of sorafenib on HepG2 cancer cells  Nature

Sorafenib for Advanced and Refractory Desmoid Tumors - The New England Journal of Medicine

Sorafenib for Advanced and Refractory Desmoid Tumors  The New England Journal of Medicine

Addition of SBRT to Systemic Therapy May Improve Outcomes in Select Patients With Locally Advance...

Addition of SBRT to Systemic Therapy May Improve Outcomes in Select Patients With Locally Advanced Hepatocellular Carcinoma  The ASCO Post

Sorafenib resistance in hepatocarcinoma: role of hypoxia-inducible factors | Experimental & Molec...

Sorafenib resistance in hepatocarcinoma: role of hypoxia-inducible factors | Experimental & Molecular Medicine  Nature

Bayer’s Sorafenib Safety Study: A Closer Look at Market Implications - TipRanks

Bayer’s Sorafenib Safety Study: A Closer Look at Market Implications  TipRanks

New knowledge of the mechanisms of sorafenib resistance in liver cancer | Acta Pharmacologica Sin...

New knowledge of the mechanisms of sorafenib resistance in liver cancer | Acta Pharmacologica Sinica  Nature

Mechanism of sorafenib resistance associated with ferroptosis in HCC - Frontiers

Mechanism of sorafenib resistance associated with ferroptosis in HCC  Frontiers

SLC27A5 promotes sorafenib-induced ferroptosis in hepatocellular carcinoma by downregulating glut...

SLC27A5 promotes sorafenib-induced ferroptosis in hepatocellular carcinoma by downregulating glutathione reductase  Nature

Sorafenib and nitazoxanide disrupt mitochondrial function and inhibit regrowth capacity in three-...

Sorafenib and nitazoxanide disrupt mitochondrial function and inhibit regrowth capacity in three-dimensional models of hepatocellular and colorectal carcinoma  Nature

Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in ...

Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells  Nature

GSTZ1 sensitizes hepatocellular carcinoma cells to sorafenib-induced ferroptosis via inhibition o...

GSTZ1 sensitizes hepatocellular carcinoma cells to sorafenib-induced ferroptosis via inhibition of NRF2/GPX4 axis  Nature

MCM2 promotes the stemness and sorafenib resistance of hepatocellular carcinoma cells via hippo s...

MCM2 promotes the stemness and sorafenib resistance of hepatocellular carcinoma cells via hippo signaling  Nature

Oral sorafenib-loaded microemulsion for breast cancer: evidences from the in-vitro evaluations an...

Oral sorafenib-loaded microemulsion for breast cancer: evidences from the in-vitro evaluations and pharmacokinetic studies  Nature

Case Report: Severe rash/desquamation induced by sorafenib in an uHCC patient and its clinical ma...

Case Report: Severe rash/desquamation induced by sorafenib in an uHCC patient and its clinical management  Frontiers

3-hydroxyanthranic acid increases the sensitivity of hepatocellular carcinoma to sorafenib by dec...

3-hydroxyanthranic acid increases the sensitivity of hepatocellular carcinoma to sorafenib by decreasing tumor cell stemness  Nature

MCL1 inhibition: a promising approach to augment the efficacy of sorafenib in NSCLC through ferro...

MCL1 inhibition: a promising approach to augment the efficacy of sorafenib in NSCLC through ferroptosis induction  Nature

RCN1 induces sorafenib resistance and malignancy in hepatocellular carcinoma by activating c-MYC ...

RCN1 induces sorafenib resistance and malignancy in hepatocellular carcinoma by activating c-MYC signaling via the IRE1α–XBP1s pathway | Cell Death Discovery  Nature

Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellu...

Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study  The Lancet

Sorafenib inhibits ossification of the posterior longitudinal ligament by blocking LOXL2-mediated...

Sorafenib inhibits ossification of the posterior longitudinal ligament by blocking LOXL2-mediated vascularization  Nature

TRIM21 mediates the synergistic effect of Olaparib and Sorafenib by degrading BRCA1 through ubiqu...

TRIM21 mediates the synergistic effect of Olaparib and Sorafenib by degrading BRCA1 through ubiquitination in TNBC  Nature

Pharmacokinetic Exposures Associated With Oral Administration of Sorafenib in Dogs With Spontaneo...

Pharmacokinetic Exposures Associated With Oral Administration of Sorafenib in Dogs With Spontaneous Tumors  Frontiers

UBQLN1 mediates sorafenib resistance through regulating mitochondrial biogenesis and ROS homeosta...

UBQLN1 mediates sorafenib resistance through regulating mitochondrial biogenesis and ROS homeostasis by targeting PGC1β in hepatocellular carcinoma | Signal Transduction and Targeted Therapy  Nature

Reversal of sorafenib resistance in hepatocellular carcinoma: epigenetically regulated disruption...

Reversal of sorafenib resistance in hepatocellular carcinoma: epigenetically regulated disruption of 14-3-3η/hypoxia-inducible factor-1α  Nature

Midkine inhibition enhances anti-PD-1 immunotherapy in sorafenib-treated hepatocellular carcinoma...

Midkine inhibition enhances anti-PD-1 immunotherapy in sorafenib-treated hepatocellular carcinoma via preventing immunosuppressive MDSCs infiltration  Nature

The PI3K inhibitor copanlisib synergizes with sorafenib to induce cell death in hepatocellular ca...

The PI3K inhibitor copanlisib synergizes with sorafenib to induce cell death in hepatocellular carcinoma  Nature

YAP/TAZ and ATF4 drive resistance to Sorafenib in hepatocellular carcinoma by preventing ferropto...

YAP/TAZ and ATF4 drive resistance to Sorafenib in hepatocellular carcinoma by preventing ferroptosis  EMBO Press

Sorafenib maintenance after allogeneic haemopoietic stem-cell transplantation in patients with FL...

Sorafenib maintenance after allogeneic haemopoietic stem-cell transplantation in patients with FLT3-ITD acute myeloid leukaemia: long-term follow-up of an open-label, multicentre, randomised, phase 3 trial  The Lancet

Sorafenib and its derivative SC-1 exhibit antifibrotic effects through signal transducer and acti...

Sorafenib and its derivative SC-1 exhibit antifibrotic effects through signal transducer and activator of transcription 3 inhibition  PNAS

Sorafenib tosylate inhibits directly necrosome complex formation and protects in mouse models of ...

Sorafenib tosylate inhibits directly necrosome complex formation and protects in mouse models of inflammation and tissue injury  Nature

TLR3 activation enhances antitumor effects of sorafenib in hepatocellular carcinoma by activating...

TLR3 activation enhances antitumor effects of sorafenib in hepatocellular carcinoma by activating NK cell functions through ERK and NF-κB pathways  Nature

Phosphorylated FOXQ1, a novel substrate of JNK1, inhibits sorafenib-induced ferroptosis by activa...

Phosphorylated FOXQ1, a novel substrate of JNK1, inhibits sorafenib-induced ferroptosis by activating ETHE1 in hepatocellular carcinoma | Cell Death & Disease  Nature

Impact of glucose metabolism on PD-L1 expression in sorafenib-resistant hepatocellular carcinoma ...

Impact of glucose metabolism on PD-L1 expression in sorafenib-resistant hepatocellular carcinoma cells  Nature

Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RES...

Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial  The Lancet

Pre-sarcopenia determines post-progression outcomes in advanced hepatocellular carcinoma after so...

Pre-sarcopenia determines post-progression outcomes in advanced hepatocellular carcinoma after sorafenib failure  Nature

Real-world experience of sorafenib maintenance after allogeneic hematopoietic stem cell transplan...

Real-world experience of sorafenib maintenance after allogeneic hematopoietic stem cell transplantation for FLT3-ITD AML reveals high rates of toxicity-related treatment interruption  Frontiers

Discovery points to new approach to treating liver cancer - Purdue University

Discovery points to new approach to treating liver cancer  Purdue University

Formulation development, characterization, and evaluation of sorafenib-loaded PLGA–chitosan nanop...

Formulation development, characterization, and evaluation of sorafenib-loaded PLGA–chitosan nanoparticles  Frontiers

Targeting Aurora-A inhibits tumor progression and sensitizes thyroid carcinoma to Sorafenib by de...

Targeting Aurora-A inhibits tumor progression and sensitizes thyroid carcinoma to Sorafenib by decreasing PFKFB3-mediated glycolysis  Nature

Ets1 mediates sorafenib resistance by regulating mitochondrial ROS pathway in hepatocellular carc...

Ets1 mediates sorafenib resistance by regulating mitochondrial ROS pathway in hepatocellular carcinoma  Nature

Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular ...

Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial  The Lancet

IL-22 signaling promotes sorafenib resistance in hepatocellular carcinoma via STAT3/CD155 signali...

IL-22 signaling promotes sorafenib resistance in hepatocellular carcinoma via STAT3/CD155 signaling axis  Frontiers

Intracellular Magnetic Hyperthermia Sensitizes Sorafenib to Orthotopic Hepatocellular Carcinoma V...

Intracellular Magnetic Hyperthermia Sensitizes Sorafenib to Orthotopic Hepatocellular Carcinoma Via Amplified Ferroptosis  ACS Publications

Impact of adjuvant sorafenib treatment after local ablation for HCC in the phase II SORAMIC trial...

Impact of adjuvant sorafenib treatment after local ablation for HCC in the phase II SORAMIC trial  ScienceDirect.com

CD24 regulates sorafenib resistance via activating autophagy in hepatocellular carcinoma | Cell D...

CD24 regulates sorafenib resistance via activating autophagy in hepatocellular carcinoma | Cell Death & Disease  Nature

Desmoid Tumors and Celecoxib with Sorafenib - The New England Journal of Medicine

Desmoid Tumors and Celecoxib with Sorafenib  The New England Journal of Medicine

Effect of Spheroidal Age on Sorafenib Diffusivity and Toxicity in a 3D HepG2 Spheroid Model - Nature

Effect of Spheroidal Age on Sorafenib Diffusivity and Toxicity in a 3D HepG2 Spheroid Model  Nature

Overcoming sorafenib evasion in hepatocellular carcinoma using CXCR4-targeted nanoparticles to co...

Overcoming sorafenib evasion in hepatocellular carcinoma using CXCR4-targeted nanoparticles to co-deliver MEK-inhibitors  Nature

BH3-only protein expression determines hepatocellular carcinoma response to sorafenib-based treat...

BH3-only protein expression determines hepatocellular carcinoma response to sorafenib-based treatment  Nature

Cabozantinib Is Safe and Tolerable in Sorafenib-Intolerant HCC - OncLive

Cabozantinib Is Safe and Tolerable in Sorafenib-Intolerant HCC  OncLive